Lineage Cell Therapeutics to Present at September 2025 Investor Conferences

(LCTX) CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf”, cell therapies for serious neurological and ophthalmic conditions, today announced that Brian M. Culley, Lineage’s Chief Executive Officer, will be presenting at the H.C. Wainwright 27th Annual Global Investment Conference, on September 8, 2025, at 11:30am ET and at Baird's 2025 Global Healthcare Conference, on